PICO Portalanswers from OpenAlex & ORCID
Robert Bissonnette
ResearcherPublications, citations & collaboration network
Robert Bissonnette is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Robert Bissonnette have?
PICO Portalindexed works
Robert Bissonnette has 477 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Robert Bissonnette have?
PICO Portalcitation count
Robert Bissonnette has 18,029 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Robert Bissonnette?
PICO Portalh-index
Robert Bissonnette has an h-index of 74 in OpenAlex.
What is the i10-index of Robert Bissonnette?
PICO Portali10-index
Robert Bissonnette has an i10-index of 231 in OpenAlex.
What is the ORCID of Robert Bissonnette?
PICO Portalorcid
The ORCID for Robert Bissonnette is on the source record.
What is the OpenAlex record for Robert Bissonnette?
PICO Portalopenalex
The OpenAlex for Robert Bissonnette is on the source record.
What are the most-cited papers on Robert Bissonnette?
PICO Portalmost cited works
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
Emma Guttman‐Yassky, Robert Bissonnette, Benjamin Ungar, Mayte Suárez‐Fariñas, Marius Ardeleanu, Hitokazu Esaki, Maria Suprun, Yeriel Estrada, Hui Xu, Xiangyu Peng, Jonathan I. Silverberg, Alan Menter, James G. Krueger, Rick Zhang, Usman Chaudhry, Brian N. Swanson, Neil M.H. Graham, Gianluca Pirozzi, George D. Yancopoulos, Jennifer D. Hamilton
Topical tofacitinib for atopic dermatitis: a phase <scp>II</scp> a randomized trial
Robert Bissonnette, Kim Papp, Yves Poulin, Melinda Gooderham, Maitreyi Raman, Lotus Mallbris, C. Wang, Vivek S. Purohit, Carla Mamolo, Jocelyne Papacharalambous, W.C. Ports
Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial
Thomas Ruzicka, Charles Lynde, Gregor B. E. Jemec, Thomas L. Diepgen, J. Berth‐Jones, Pieter‐Jan Coenraads, Andrzej Kaszuba, Robert Bissonnette, E. Varjonen, Péter Holló, F. Cambazard, M. Lahfa, Peter Elsner, Fredrik Nyberg, Åke Svensson, Thomas C. Brown, Martin Harsch, J. Maares
Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trials
Eric L. Simpson, J.‐P. Lacour, Lynda Spelman, Ricardo Galimberti, Lawrence F. Eichenfield, Robert Bissonnette, Brett King, Jacob P. Thyssen, Jonathan I. Silverberg, Thomas Bieber, Kenji Kabashima, Yuichiro Tsunemi, Antonio Costanzo, Emma Guttman‐Yassky, Lisa A. Beck, Jonathan Janes, Amy M. DeLozier, Margaret Gamalo, Dennis Brinker, T. Cardillo, Fabio P. Nunes, Amy S. Paller, Andreas Wollenberg, Kristian Reich
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Kenneth B. Gordon, Kristina Callis Duffin, Robert Bissonnette, Jörg C. Prinz, Yasmine Wasfi, Shu Li, Yaung‐Kaung Shen, Philippe Szapary, B. Randazzo, Kristian Reich